P53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer

Nan Yung Hsu, Jeng Yuan Wu, Xiyong Liu, Yun Yen, Chih Yi Chen, Ming Chih Chou, Huei Lee, Ya Wen Cheng

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

p53R2 is a small subunit of ribonucleotide reductase (RR) which has 80% homology to hRRM2 and metastasis suppressing potential. Previous reports suggested that the expression of p53R2 is used as a prognostic factor and chemo-therapy response indicator in several types of cancer. This study aimed to elucidate the association of p53R2 expression and the clinicopathological characteristics of early stage non small cell lung cancer (NSCLC). Immuno histochemistry was conducted on a tissue array including 92 early stage NSCLC samples. Correlations between p53R2 and clinicopathological factors, recurrence/metastasis and outcomes were analyzed. The analyses showed that there was no correlation between p53R2 expression and the clinicopathological factors. Among disease-free patients during follow-up, patients with p53R2(+) had a better outcome than those with p53R2(-) (P=0.022). By using Cox multivariate regression analysis, p53R2 (risk factor 3.801; 95% CI 1.004-9.454; P=0.044) served as a prognostic biomarker in the prediction of the survival rate for NSCLC patients. Detection of the RR subunit p53R2 may therefore be a useful prognostic marker in early stage NSCLC.

Original languageEnglish
Pages (from-to)609-613
Number of pages5
JournalOncology Letters
Volume1
Issue number4
DOIs
Publication statusPublished - Jul 2010
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Biomarkers
Ribonucleotide Reductases
Neoplasm Metastasis
Multivariate Analysis
Survival Rate
Regression Analysis
Recurrence
Neoplasms
Therapeutics

Keywords

  • Early stage
  • Non-small cell lung cancer
  • P53R2
  • Ribonucleotide reductase

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hsu, N. Y., Wu, J. Y., Liu, X., Yen, Y., Chen, C. Y., Chou, M. C., ... Cheng, Y. W. (2010). P53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer. Oncology Letters, 1(4), 609-613. https://doi.org/10.3892/ol_00000108

P53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer. / Hsu, Nan Yung; Wu, Jeng Yuan; Liu, Xiyong; Yen, Yun; Chen, Chih Yi; Chou, Ming Chih; Lee, Huei; Cheng, Ya Wen.

In: Oncology Letters, Vol. 1, No. 4, 07.2010, p. 609-613.

Research output: Contribution to journalArticle

Hsu, NY, Wu, JY, Liu, X, Yen, Y, Chen, CY, Chou, MC, Lee, H & Cheng, YW 2010, 'P53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer', Oncology Letters, vol. 1, no. 4, pp. 609-613. https://doi.org/10.3892/ol_00000108
Hsu, Nan Yung ; Wu, Jeng Yuan ; Liu, Xiyong ; Yen, Yun ; Chen, Chih Yi ; Chou, Ming Chih ; Lee, Huei ; Cheng, Ya Wen. / P53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer. In: Oncology Letters. 2010 ; Vol. 1, No. 4. pp. 609-613.
@article{ac2baa7da7214aa8876e7804492068ef,
title = "P53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer",
abstract = "p53R2 is a small subunit of ribonucleotide reductase (RR) which has 80{\%} homology to hRRM2 and metastasis suppressing potential. Previous reports suggested that the expression of p53R2 is used as a prognostic factor and chemo-therapy response indicator in several types of cancer. This study aimed to elucidate the association of p53R2 expression and the clinicopathological characteristics of early stage non small cell lung cancer (NSCLC). Immuno histochemistry was conducted on a tissue array including 92 early stage NSCLC samples. Correlations between p53R2 and clinicopathological factors, recurrence/metastasis and outcomes were analyzed. The analyses showed that there was no correlation between p53R2 expression and the clinicopathological factors. Among disease-free patients during follow-up, patients with p53R2(+) had a better outcome than those with p53R2(-) (P=0.022). By using Cox multivariate regression analysis, p53R2 (risk factor 3.801; 95{\%} CI 1.004-9.454; P=0.044) served as a prognostic biomarker in the prediction of the survival rate for NSCLC patients. Detection of the RR subunit p53R2 may therefore be a useful prognostic marker in early stage NSCLC.",
keywords = "Early stage, Non-small cell lung cancer, P53R2, Ribonucleotide reductase",
author = "Hsu, {Nan Yung} and Wu, {Jeng Yuan} and Xiyong Liu and Yun Yen and Chen, {Chih Yi} and Chou, {Ming Chih} and Huei Lee and Cheng, {Ya Wen}",
year = "2010",
month = "7",
doi = "10.3892/ol_00000108",
language = "English",
volume = "1",
pages = "609--613",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - P53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer

AU - Hsu, Nan Yung

AU - Wu, Jeng Yuan

AU - Liu, Xiyong

AU - Yen, Yun

AU - Chen, Chih Yi

AU - Chou, Ming Chih

AU - Lee, Huei

AU - Cheng, Ya Wen

PY - 2010/7

Y1 - 2010/7

N2 - p53R2 is a small subunit of ribonucleotide reductase (RR) which has 80% homology to hRRM2 and metastasis suppressing potential. Previous reports suggested that the expression of p53R2 is used as a prognostic factor and chemo-therapy response indicator in several types of cancer. This study aimed to elucidate the association of p53R2 expression and the clinicopathological characteristics of early stage non small cell lung cancer (NSCLC). Immuno histochemistry was conducted on a tissue array including 92 early stage NSCLC samples. Correlations between p53R2 and clinicopathological factors, recurrence/metastasis and outcomes were analyzed. The analyses showed that there was no correlation between p53R2 expression and the clinicopathological factors. Among disease-free patients during follow-up, patients with p53R2(+) had a better outcome than those with p53R2(-) (P=0.022). By using Cox multivariate regression analysis, p53R2 (risk factor 3.801; 95% CI 1.004-9.454; P=0.044) served as a prognostic biomarker in the prediction of the survival rate for NSCLC patients. Detection of the RR subunit p53R2 may therefore be a useful prognostic marker in early stage NSCLC.

AB - p53R2 is a small subunit of ribonucleotide reductase (RR) which has 80% homology to hRRM2 and metastasis suppressing potential. Previous reports suggested that the expression of p53R2 is used as a prognostic factor and chemo-therapy response indicator in several types of cancer. This study aimed to elucidate the association of p53R2 expression and the clinicopathological characteristics of early stage non small cell lung cancer (NSCLC). Immuno histochemistry was conducted on a tissue array including 92 early stage NSCLC samples. Correlations between p53R2 and clinicopathological factors, recurrence/metastasis and outcomes were analyzed. The analyses showed that there was no correlation between p53R2 expression and the clinicopathological factors. Among disease-free patients during follow-up, patients with p53R2(+) had a better outcome than those with p53R2(-) (P=0.022). By using Cox multivariate regression analysis, p53R2 (risk factor 3.801; 95% CI 1.004-9.454; P=0.044) served as a prognostic biomarker in the prediction of the survival rate for NSCLC patients. Detection of the RR subunit p53R2 may therefore be a useful prognostic marker in early stage NSCLC.

KW - Early stage

KW - Non-small cell lung cancer

KW - P53R2

KW - Ribonucleotide reductase

UR - http://www.scopus.com/inward/record.url?scp=77954899556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954899556&partnerID=8YFLogxK

U2 - 10.3892/ol_00000108

DO - 10.3892/ol_00000108

M3 - Article

VL - 1

SP - 609

EP - 613

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 4

ER -